Antiviral therapy with interferon (IFN) has long been the only available option to modify the course of the infection, since in many patients with a sustained virological response (SVR), it succeeded in preventing the onset of life-threatening end-stage complications of hepatitis C [2,3,4,5,6,7]. This evidence concerns the gene IFNA1 and infection.